Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Want to see AU:VBS full AI Analyst Report?
Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.11
▼(-38.89% Downside)
Action:Reiterated
Date:05/20/26
The score is driven primarily by weak financial performance (shrinking revenue, persistent losses and cash burn, and negative equity increasing financing risk). Technical indicators add downside pressure (price below key moving averages, negative MACD, very low RSI). Valuation is not supportive because the negative P/E reflects unprofitable operations and there is no dividend yield provided.
Positive Factors
High gross margins
Consistently high gross margins indicate strong unit economics and scalable product-level profitability for VBS's therapies. Over the medium term this supports attractive licensing economics and means successful asset transfers or partnerships could convert product-level strength into durable cash flows if operating expenses are controlled.
Negative Factors
Sharp revenue decline
A 45.9% year-on-year revenue drop is a durable red flag for commercial traction or contract timing. Sustained revenue contraction weakens internal funding for R&D and operations, harms partner negotiation leverage, and increases reliance on external capital, making execution of clinical and commercialization plans harder.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Consistently high gross margins indicate strong unit economics and scalable product-level profitability for VBS's therapies. Over the medium term this supports attractive licensing economics and means successful asset transfers or partnerships could convert product-level strength into durable cash flows if operating expenses are controlled.
Read all positive factors
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.07M
Dividend YieldN/A
Average Volume (3M)97.35K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue GrowthN/A
EPS Growth37.88%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,494,150
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vectus Biosystems Limited Business Overview & Revenue Model
Company Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead ...
How the Company Makes Money
Vectus Biosystems Limited generates revenue primarily through the commercialization of its patented drug candidates and therapies. The company monetizes its intellectual property by licensing agreements with pharmaceutical companies or partnership...
Vectus Biosystems Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.47K | 478.18K | 1.14M | 1.35M | 1.30M | 180.00 |
| Gross Profit | 82.89K | 478.18K | 1.14M | 1.31M | 1.28M | 1.02M |
| EBITDA | -1.39M | -1.69M | -2.27M | -3.19M | -3.28M | -3.71M |
| Net Income | -1.41M | -1.78M | -2.34M | -3.45M | -3.99M | -3.86M |
Balance Sheet | ||||||
| Total Assets | 461.65K | 782.66K | 2.03M | 4.63M | 3.94M | 6.98M |
| Cash, Cash Equivalents and Short-Term Investments | 330.50K | 250.99K | 808.97K | 2.95M | 1.28M | 5.78M |
| Total Debt | 467.10K | 200.00K | 28.93K | 70.21K | 6.90M | 8.68M |
| Total Liabilities | 1.27M | 1.04M | 539.26K | 1.11M | 8.36M | 9.88M |
| Stockholders Equity | -806.29K | -256.62K | 1.49M | 3.52M | -4.42M | -2.90M |
Cash Flow | ||||||
| Free Cash Flow | -830.47K | -830.09K | -2.10M | -2.37M | -4.46M | -3.26M |
| Operating Cash Flow | -830.47K | -830.09K | -2.03M | -2.35M | -4.44M | -3.26M |
| Investing Cash Flow | -70.00K | 101.03K | -67.90K | -17.13K | -21.00K | 0.00 |
| Financing Cash Flow | 421.07K | 171.07K | -41.28K | 4.04M | -34.55K | 6.35M |
Vectus Biosystems Limited Technical Analysis
Negative
0.18
Price Trends
0.13
Negative
0.13
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
45.90
Neutral
65.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.13, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 65.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VBS.
Vectus Biosystems Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$6.75M | -1.94 | -119.12% | ― | ― | -21.43% | |
46 Neutral | AU$12.03M | -2.11 | -218.76% | ― | 76.94% | 42.95% | |
45 Neutral | AU$2.17M | -1.06 | -32.19% | ― | ― | 75.44% | |
44 Neutral | AU$10.62M | -1.43 | 1068.18% | ― | ― | 40.85% | |
41 Neutral | AU$7.07M | -4.35 | 265.12% | ― | ― | 37.88% | |
40 Underperform | AU$3.16M | -2.65 | -109.45% | ― | ― | 43.14% |
* Healthcare Sector Average
AU:VBS
Vectus Biosystems Limited
0.12
0.07
155.56%
AU:BIT
Biotron
―
―
―
AU:CMB
Regeneus Ltd.
0.44
0.20
79.59%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Raises $791,000 to Accelerate VB0004 Clinical Trial
May 27, 2026
Vectus Biosystems Limited has raised $791,000 through the issue of 7,910,000 new fully paid ordinary shares to sophisticated investors at $0.10 per share under a recently announced placement. The funds will be directed primarily to accelerating th...
Vectus Biosystems Seeks ASX Quotation for 7.9 Million New Shares
May 27, 2026
Vectus Biosystems Limited has applied to the ASX for quotation of 7,910,000 new ordinary fully paid shares, with an issue date of 27 May 2026. The move formalises the listing of securities previously flagged to the market, potentially broadening t...
Vectus Biosystems Plans Share and Option Issue to Raise Capital
May 22, 2026
Vectus Biosystems Limited has lodged an Appendix 3B outlining a proposed placement or similar issue of new securities on the ASX. The company plans to issue up to 7,910,000 ordinary fully paid shares and an equal number of options exercisable at $...
Vectus Biosystems Raises Capital to Accelerate VB0004 Fibrosis Trials
May 22, 2026
Vectus Biosystems has raised approximately $0.8 million through a placement of 7.91 million new shares at $0.10 each to institutional and sophisticated investors, with attaching options subject to shareholder approval. The capital will strengthen ...
Vectus Biosystems to List Additional Shares on ASX After Option Conversions
May 12, 2026
Vectus Biosystems Limited has applied to the ASX for quotation of 41,817 new ordinary fully paid shares, to be issued on 12 May 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instrume...
Vectus Biosystems Issues New Shares Linked to Executive Appointment
May 8, 2026
Vectus Biosystems has issued 109,000 new fully paid ordinary shares as part of the employment agreement for its newly appointed Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza. The move signals a strengthening of the company...
Vectus Biosystems issues new shares to incoming CEO-CTO
May 8, 2026
Vectus Biosystems has applied to the ASX for quotation of 109,000 new fully paid ordinary shares, issued to its newly appointed Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza. The share grant, made under the terms of her em...
Vectus Biosystems Grants 981,000 Unquoted Options Under Employee Scheme
May 8, 2026
Vectus Biosystems Limited has issued 981,000 unquoted options under its employee incentive scheme, with no consideration payable on exercise. These options, which will not be quoted on the ASX, are designed to reward and retain staff, signalling t...
Vectus Biosystems names Dr Tara Speranza CEO and CTO to drive next growth phase
May 7, 2026
Vectus Biosystems has appointed Dr Tara Speranza as both Chief Executive Officer and Chief Technology Officer, formalising a relationship that began with her consulting work in 2025 and leveraging her extensive background in translational drug dev...
Vectus Biosystems Secures XORTX Equity in VB4‑P5 Deal as Licensing Push Intensifies
Apr 30, 2026
Vectus Biosystems has completed the sale of its VB4‑P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, receiving a 9.9% equity stake and pre‑funded warrants in lieu of cash, ensuring ongoing exposure to the asset’...
Vectus Biosystems Sells Renal Fibrosis Drug to XORTX for Strategic Equity Stake
Apr 13, 2026
Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, receiving a 9.9% equity stake and a large block of pre-funded warrants in lieu of cash. The deal transfers patents and VB4-P5 da...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.